Recall archive / FDA company announcement

Gilead: Veklury (remdesivir) for Injection — FDA announcement Sep 23, 2024

Reported terminated

A company announcement posted by FDA. The listing date can differ from the original announcement date. The absence of a termination marker does not prove the recall is currently ongoing.

Source date Sep 23, 2024. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.

Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.

What the record says

Product: Veklury (remdesivir) for Injection
Reason: Due to Presence of Glass Particle
Classification: Not supplied
Recalling firm: Gilead Sciences, Inc.
Quantity: Not supplied
Agency-reported status: Terminated in FDA listing
Source record identifier: 8c2e2a93f865597d

Open the official record

Lot and product identifiers

Label field	Details supplied by the agency
Lot, code or applicability	FOR IMMEDIATE RELEASE - Foster City, Calif., September 20, 2024 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is issuing a voluntary recall of one lot of Veklury® (remdesivir) for Injection 100 mg/vial, to the consumer level. Gilead received a customer complaint and confirmed the presence of a glass particle in the vial during the company's investigation.; The product being recalled is the lyophilized form of Veklury® (remdesivir) for Injection 100 mg/vial packaged in single dose clear glass vials in powder form. Veklury lot # 47035CFA was distributed nationwide in the United States, beginning 16 July 2024. NDC, lot, expiration date and distribution dates can be found in the table below.; Gilead is notifying its distributors and customers via UPS next day air mail to pharmacies and is facilitating the return of any remaining vials from the affected lot. Facilities that have Veklury® (remdesivir) for Injection 100 mg/vial which is being recalled should stop using the affected lot and return the product vials per the instructions in the letter.; Product Description \| NDC \| Lot # \| Expiration Date \| Distribution Date to Wholesalers; Veklury® (remdesivir 100mg for injection) \| 61958-2901-02 \| 47035CFA \| Exp. Date 11/2025 \| 07/16/2024 to 08/07/2024

Label field

Details supplied by the agency

Lot, code or applicability

FOR IMMEDIATE RELEASE - Foster City, Calif., September 20, 2024 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is issuing a voluntary recall of one lot of Veklury® (remdesivir) for Injection 100 mg/vial, to the consumer level. Gilead received a customer complaint and confirmed the presence of a glass particle in the vial during the company's investigation.; The product being recalled is the lyophilized form of Veklury® (remdesivir) for Injection 100 mg/vial packaged in single dose clear glass vials in powder form. Veklury lot # 47035CFA was distributed nationwide in the United States, beginning 16 July 2024. NDC, lot, expiration date and distribution dates can be found in the table below.; Gilead is notifying its distributors and customers via UPS next day air mail to pharmacies and is facilitating the return of any remaining vials from the affected lot. Facilities that have Veklury® (remdesivir) for Injection 100 mg/vial which is being recalled should stop using the affected lot and return the product vials per the instructions in the letter.; Product Description | NDC | Lot # | Expiration Date | Distribution Date to Wholesalers; Veklury® (remdesivir 100mg for injection) | 61958-2901-02 | 47035CFA | Exp. Date 11/2025 | 07/16/2024 to 08/07/2024

Match all identifying details in the current notice. A brand name alone is not enough.

Product tables from the announcement

These identifying details come from the company announcement posted by FDA. Check the current notice for revisions.

FDA company announcement, table 1
Product Description	NDC	Lot #	Expiration Date	Distribution Date to Wholesalers
Veklury® (remdesivir 100mg for injection)	61958-2901-02	47035CFA	Exp. Date 11/2025	07/16/2024 to 08/07/2024

Announcement retrieved Oct 1, 2026. Official announcement.

Distribution

The product being recalled is the lyophilized form of Veklury® (remdesivir) for Injection 100 mg/vial packaged in single dose clear glass vials in powder form. Veklury lot # 47035CFA was distributed nationwide in the United States, beginning 16 July 2024. NDC, lot, expiration date and distribution dates can be found in the table below.

States below are derived from the distribution text, including nationwide wording. They are not inferred from the firm's address.

Dates in the source

Fda listing date: Sep 23, 2024
Company announcement date: Sep 20, 2024

FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.